EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Get the Brief in your inbox

A daily, SEC-grounded read on the market — movers, earnings, and our boldest calls. Free.

EEDGAR/calls

SEC-grounded equity research — opinionated calls reasoned over real filings.

Research

  • The Brief
  • Markets
  • All Stocks
  • Screener
  • Discover
  • Research
  • The Flip Side
  • Track record

Tools

  • Compare
  • Congress trades
  • Events
  • Filing search
  • Groups
  • Trending
  • News

More

  • Pricing
  • Community
  • Newsletter
  • Developers / API
  • Account
DisclosuresTermsPrivacy

Research & education only — not financial advice. EDGAR is not a registered investment adviser; calls are impersonal, generated from SEC filings and a delayed/third-party price feed, and may be wrong or out of date. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates — see Disclosures. Do your own research.

EDGAR® is a registered trademark of the U.S. Securities and Exchange Commission. EDGAR/calls is not affiliated with, endorsed by, or approved by the U.S. Securities and Exchange Commission.

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity

Pulling SEC filings + quote and writing the call…

EEDGAR/calls
The BriefMarketsAll StocksNewsScreenerCommunity
← New search
Home›Stocks›DRDB

DRDB

Roman DBDR Acquisition Corp. II

Next earnings ≈ Aug 5, 2026 · est. from filing cadence

Hold
$10.55
▲ +0.19%
$10.55▲ +2.43%
over 1Y
L $10.25H $10.56
Earnings Dividend Split Congress buy Congress sellGrouped by date · hover a pin to expand
Today+0.2%
1W+0.2%
1M-0.1%
3M+0.7%
YTD+1.2%
1Y+2.4%
OverviewFinancialsValuationQualityTimelineFilings
Rating
Hold
Quality
C
Valuation
Fair value
Filings
Flagged
Hold
Conviction
Horizon
Medium (3–12mo)

Conservative balance sheet (liabilities/equity -1.41x).

Liabilities / equity -1.41x · latest

Roman DBDR Acquisition Corp. II shows limited reported revenue.

Supporting the case: conservative balance sheet (liabilities/equity -1.41x).

Financials · annual, by fiscal year

Line itemFY25
Revenue—
Gross profit—
Operating income-$2.25M
Net income$7.74M
Diluted EPS—
Net margin—

Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.

Key statistics

Valuation

Enterprise value$323M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield2.4%
FCF yield—

Quality & risk

ROIC (est.)—
Free cash flow—
Total debt—
Net cash$183K

Capital returns

Buyback yield—
Dividend yield (est.)—
Shareholder yield—

Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.

Disclosure timeline

SEC · 8-Ks + reports
Red flag in recent filings — late filing notice (2026-05-15). Worth a closer look.
  1. 8-K Officer / director change2026-06-02
  2. 10-Q Quarterly report2026-05-20
  3. 8-K Officer / director change2026-05-15
  4. NT 10-Q Late filing notice2026-05-15
  5. 8-K Officer / director change2026-04-28
  6. 10-K Annual report2026-03-04
  7. 8-K Material agreement2026-02-27
  8. 10-Q Quarterly report2025-11-13
  9. 10-Q Quarterly report2025-10-23

Recent filings

all on EDGAR ↗
8-KPeriod ending 2026-05-272026-06-02open ↗10-QPeriod ending 2026-03-312026-05-20open ↗3Period ending 2026-05-112026-05-15open ↗NT 10-QPeriod ending 2026-03-312026-05-15open ↗8-KPeriod ending 2026-05-112026-05-15open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13GFiling2026-05-15open ↗SCHEDULE 13G/AFiling2026-05-14open ↗SCHEDULE 13GFiling2026-05-07open ↗3Period ending 2026-04-272026-04-30open ↗8-KPeriod ending 2026-04-222026-04-28open ↗10-KPeriod ending 2025-12-312026-03-04open ↗

Quality score

C
ValueGrowthProfitHealthMom.
Value—
Growth—
Profitability—
Financial healthF
MomentumA
  • ✓Profitable (positive net income)
  • ✓Liabilities below 2× equity
10.2552-week10.56
Revenue
—
Net margin
—
ROE
—
P/E
—

SEC fundamentals · FY 2025

Net income$7.74M
Operating income-$2.25M
Cash & equivalents$183K-85.6%
Total assets$242M+19.1%
Total liabilities$1.10M+263.1%
Stockholders' equity-$778K
L/E: -1.41x

Frequently asked

Is Roman DBDR Acquisition Corp. II (DRDB) a buy?
DRDB currently carries a Hold rating with 2/5 conviction, derived from its latest SEC filings. Conservative balance sheet (liabilities/equity -1.41x).
What is Roman DBDR Acquisition Corp. II's quality score?
DRDB scores 58.637467669725766/100 (grade C) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.

Sources: SEC EDGAR (CIK 0002032528, latest 10-Q filed 2026-05-20) · EODHD · as of 7/4/2026, 10:00:49 AM.

Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.

Recent news

market news →
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating The Merger—DRDB, AES, FONR, and DVNBullish
globenewswire.com· 2026-03-03
Roman DBDR Acquisition Corp. II receives Nasdaq deficiency letterBullish
seekingalpha.com· 2025-09-18
Roman DBDR Acquisition Corp. II Announces Receipt of Nasdaq Deficiency LetterBullish
finance.yahoo.com· 2025-09-18

Vs tracked universe

compare →

1195 tracked peers · median

EDGAR Score59 vs 67
Revenue growth— vs 7.5%
Net margin— vs 10.0%
Return on equity— vs 12.0%
P/E— vs 26.2